WASHINGTON (AP) — Federal regulators on Friday approved a new drug from Johnson & Johnson for use in treating chronic hepatitis C infections.

The U.S. Food and Drug Administration said it approved the drug, a protease inhibitor that blocks a protein needed by the virus to replicate.

Recommended Stories

Obama says he was a Cheesecake Factory regular for a decade in retort to Trump

Haley Stevens’s Democratic fiance backs Mike Rogers, says el Sayed imperils Jewish community

MAHA heavyweights try to put Lahn over the top in Iowa governor’s race